Shilpa Patil

Shilpa Patil

Auto-generated profile, based on publicly available information

Shilpa Patil

Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
RERajasegaran Elumalai
Rajasegaran Elumalai
SPShilpa Patil
Shilpa Patil
NMNaseer Maliyakkal
Naseer Maliyakkal
ARAnnapoorni Rangarajan
Annapoorni Rangarajan
PKPaturu Kondaiah
Paturu Kondaiah
ARAshok M. Raichur
Ashok M. Raichur

6 May 2015 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SPShilpa S. Patil
Shilpa S. Patil
RRReema Railkar
Reema Railkar
MSMonalisa Swain
Monalisa Swain
HAHanudatta S. Atreya
Hanudatta S. Atreya
RDRajan R. Dighe
Rajan R. Dighe
PKPaturu Kondaiah
Paturu Kondaiah

12 December 2014 in Inorganic Chemistry
Verified
Journal Article
Closed access
KMKoushambi Mitra
Koushambi Mitra
SPShilpa Patil
Shilpa Patil
PKPaturu Kondaiah
Paturu Kondaiah
ACAkhil R. Chakravarty
Akhil R. Chakravarty

16 June 2013 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
PSPriyanka Sehgal
Priyanka Sehgal
NKNeeraj Kumar
Neeraj Kumar
VKVaruvar Rajesh Praveen Kumar
Varuvar Rajesh Praveen Kumar
SPShilpa Patil
Shilpa Patil
ABAnimesh Bhattacharya
Animesh Bhattacharya
PKPaturu Kondaiah
Paturu Kondaiah
Background: Insulin like growth factor binding proteins modulate the mitogenic and pro survival effects of IGF. Elevated expression of IGFBP2 is associated with progression of tumors that include prostate, ovarian, glioma among others. Though implicated in the progression of breast cancer, the molecular mechanisms involved in IGFBP2 actions are not well defined. This study investigates the molecular targets and biological pathways targeted by IGFBP2 in breast cancer. Methods: Transcriptome analysis of breast tumor cells (BT474) with stable knockdown of IGFBP2 and breast tumors having differential expression of IGFBP2 by immunohistochemistry was performed using microarray. Differential gene expression was established using R-Bioconductor package. For validation, gene expression was determined by qPCR. Inhibitors of IGF1R and integrin pathway were utilized to study the mechanism of regulation of β-catenin. Immunohistochemical and immunocytochemical staining was performed on breast tumors and experimental cells, respectively for β-catenin and IGFBP2 expression. Results: Knockdown of IGFBP2 resulted in differential expression of 2067 up regulated and 2002 down regulated genes in breast cancer cells. Down regulated genes principally belong to cell cycle, DNA replication, repair, p53 signaling, oxidative phosphorylation, Wnt signaling. Whole genome expression analysis of breast tumors with or without IGFBP2 expression indicated changes in genes belonging to Focal adhesion, Map kinase and Wnt signaling pathways. Interestingly, IGFBP2 knockdown clones showed reduced expression of β- catenin compared to control cells which was restored upon IGFBP2 re-expression. The regulation of β-catenin by IGFBP2 was found to be IGF1R and integrin pathway dependent. Furthermore, IGFBP2 and β-catenin are co-ordinately overexpressed in breast tumors and correlate with lymph node metastasis. Conclusion: This study highlights regulation of β-catenin by IGFBP2 in breast cancer cells and most importantly, combined expression of IGFBP2 and β-catenin is associated with lymph node metastasis of breast tumors.

7 January 2014 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
VKV. R. Praveen Kumar
V. R. Praveen Kumar
PSPriyanka Sehgal
Priyanka Sehgal
BTBalram Thota
Balram Thota
SPShilpa Patil
Shilpa Patil
VSVani Santosh
Vani Santosh
PKPaturu Kondaiah
Paturu Kondaiah

2 August 2019 in Radiation Research
Verified
Journal Article
Closed access
PDF file
ECEun Joo Chung
Eun Joo Chung
JRJessica L. Reedy
Jessica L. Reedy
SKSeokjoo Kwon
Seokjoo Kwon
SPShilpa Patil
Shilpa Patil
LVLuca Valle
Luca Valle
DCDeborah E. Citrin
Deborah E. Citrin
<!-- *** Custom HTML *** --> Radiation-induced pulmonary fibrosis (RIPF) is a chronic, progressive complication of therapeutic irradiation of the thorax. It has been suggested that senescence of type II pneumocytes (AECIIs), an alveolar stem cell, plays a role in the development of RIPF through loss of replicative reserve and via senescent AECII-driven release of proinflammatory and profibrotic cytokines. Within this context, we hypothesized that arachidonate 12-lipoxygenase (12-LOX) is a critical mediator of AECII senescence and RIPF. Treatment of wild-type AECIIs with 12S-hydroxyeicosateraenoic acid (12S-HETE), a downstream product of 12-LOX, was sufficient to induce senescence in a NADPH oxidase 4 (NOX4)-dependent manner. Mice deficient in 12-LOX exhibited reduced AECII senescence, pulmonary collagen accumulation and accumulation of alternatively activated (M2) macrophages after thoracic irradiation (5 × 6 Gy) compared to wild-type mice. Conditioned media from irradiated or 12S-HETE-treated primary pneumocytes contained elevated levels of IL-4 and IL-13 compared to untreated pneumocytes. Primary macrophages treated with conditioned media from irradiated AECII demonstrated preferential M2 type polarization when AECIIs were derived from wild-type mice compared to 12-LOX-deficient mice. Together, these data identified 12-LOX as a critical component of RIPF and a therapeutic target for radiation-induced lung injury.